Treating distal calciphylaxis with therapy associated with sevelamer and bisphosphonates;Tratamiento de calcifilaxis distal con terapia asociada de sevelamer y bifosfonatos

Nefrologia

Volumn 29, Issue 1, 2009, Pages 92-93

  Leon L R ^a  

^a Diaverum Cerer SA ^*  (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CHELATING AGENT; POLYAMINE; SEVELAMER;

CALCINOSIS; CASE REPORT; DRUG COMBINATION; HUMAN; LETTER; MALE; MIDDLE AGED;

CALCIPHYLAXIS; CHELATING AGENTS; DIPHOSPHONATES; DRUG THERAPY, COMBINATION; HUMANS; MALE; MIDDLE AGED; POLYAMINES;

EID: 67650728967     PISSN: 02116995     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Letter

References (5)

1. Price PA, Faus SA, Williamson MK. Bisphosphonates alendronateand ibandronate inhibit artery calcification at doses comparable to thosethat inhibit bone resorption. Arterioscler Thromb Vasc Biol 2001;21:817-24.
2. Price PA, Omid N, Than NT Williamson MK. The aminobisphosphonate Ibandronate prevents calciphylaxis in the rat at doses that inhibit bone resorption. Calcif Tissue Int 2002;71:356-63.
3. Monney P, Nguyen QV, Perroud H. Rapid improvement of Calciphylaxis after intravenous pamidronate therapy in a patient with chronic renal failure. Nephrol Dial Transplant 2004;19:2130-2.
4. Shiraishi N, Kitamura K, Miyoshi T, Adach M, Kohda Y, Nonoguchi H, et al. Successful treatment of a patient with severe calcific uremic arteriolopathy (calciphylaxis) by etidronate disodium. Am J Kidney Dis 2006;48:151-4.
5. Hanafusa T, et al. Intractable wounds caused by calcific uremic arteriolopathy treated with bisphosphonates. J Am Acad Dermatol 2007;57(6):1021-5.